November 8, 2022

Astellas Announces Decision to Discontinue Screening & Enrollment Activities for ASP0367 (MA-0211)

PPMD is disappointed to learn that Astellas has announced its decision to discontinue further screening and enrollment activities for ASP0367 (MA-0211) in participants with Duchenne. This decision was not based on safety concerns, but due…

Learn More

November 7, 2022

Astellas Announces Decision to Discontinue Screening & Enrollment Activities for ASP0367 (MA-0211)

PPMD is disappointed to learn that Astellas has announced its decision to discontinue further screening and enrollment activities for ASP0367 (MA-0211) in participants with Duchenne. This decision was not based on safety concerns, but due…

Learn More

May 21, 2021

WATCH: ASP0367 Development Program Update (Webinar Recording)

Astellas Pharma joined PPMD for a webinar on May 19, 2021 to provide an update on the company’s ASP0367 development program. If you missed the live event, the recording can be found below.    …

Learn More

April 7, 2020

Astellas Shares Update on COVID-19 and Clinical Trials

Astellas Pharma has shared an update on clinical trial status and COVID-19. Read the Announcement from Astellas Astellas Corporate Position on COVID-19 and Clinical Trials In an effort to help ensure patient safety and alleviate…

Learn More

December 4, 2019

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

Astellas Pharma and Audentes Therapeutics announced that they have entered into a definitive agreement for Astellas to acquire Audentes. We look forward to learning more as this partnership moves forward. Read the Announcement from Audentes…

Learn More